Building a Pearl-Sarvajna Dwivedi-03/11/2014 - 6:00pm

Event Information
Event Topic: 
Building a Pearl
Event Date: 
03/11/2014 - 6:00pm
Event Location: 
Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto CA
Speaker Information
Event Speaker: 
Sarvajna Dwivedi
Event Speaker Title: 
Executive VP of R&D and Co-Founder
Event Speaker Company: 
Pearl Therapeutics
Event Speaker Bio: 

Sarvajna Dwivedi

Dr. Dwivedi, co-founder of Pearl Therapeutics and now CSO on the division at AZ has an extensive prior experience in drug development at Glaxo, Dura, Alkermes, and Nektar. He was involved in the development of over 40 molecules in various therapeutic classes and dosage forms from discovery to commercialization. At Nektar, he served as the Director of Product Development, responsible for new product identification, design, planning, and development efforts. At Alkermes, he served as the Director of Delivery Systems, responsible for the engineering and development of inhalers for multiple products. At Dura, Dr. Dwivedi led and managed formulation design and development efforts for various Spiros programs. Earlier, at Glaxo, Dr. Dwivedi was involved in the development, manufacturing, and approval of Flovent® Diskhaler, Serevent® Diskus, Advair® Diskus, Relenza® Diskhaler, and Ventolin® Evohaler. In addition to his product development experience, Dr. Dwivedi has led and conducted technical due diligence efforts for in-licensing, out-licensing and acquisition opportunities. Dr. Dwivedi holds MSc and PhD degrees in Pharmaceutical Sciences from the University of British Columbia, and M.Pharm. & B.Pharm.(Hons) from Banaras Hindu University in India.

Event Details
$6 - Students/In-transition - Members only
$11 - Early-bird Registration - Members only
$20 - Late Registration and Non-Members
$25 - Walk-ins
Event Details: 

Description: Dr. Sarvajna Dwivedi Co-founder and Chief Scientific Officer at Pearl Therapeutics will talk about how he took a small startup to a global innovation driven biopharmaceutical company, with a constant focus on value creation. He will discuss how focus on medical value creation led to massive financial value creation and will share history of Pearl Therapeutics, a company that focused on respiratory products portfolio and was acquired by Astra Zeneca in July, 2013 for upwards of $1 billion.